{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(1)"],"submitter":["Kuang L"],"pubmed_abstract":["<h4>Background</h4>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the established first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, but survival advantages in advanced-stage cases remain modest and show interpatient variability. This study seeks to delineate real-world survival outcomes in stage IV EGFR-mutant NSCLC patients undergoing treatment with EGFR-TKIs and to identify independent prognostic factors impacting overall survival (OS). The findings are expected to be a reference for clinicians in managing advanced lung cancer patients.<h4>Methods</h4>Clinical characteristics from advanced EGFR-mutant NSCLC patients who received EGFR-TKIs were retrospectively analyzed to investigate th"],"journal":["BMC pulmonary medicine"],"pagination":["114"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11907820"],"repository":["biostudies-literature"],"pubmed_title":["Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs."],"pmcid":["PMC11907820"],"pubmed_authors":["Li Y","Wang P","Zhang Y","Kuang L","Wang H"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs.","description":"<h4>Background</h4>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the established first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, but survival advantages in advanced-stage cases remain modest and show interpatient variability. This study seeks to delineate real-world survival outcomes in stage IV EGFR-mutant NSCLC patients undergoing treatment with EGFR-TKIs and to identify independent prognostic factors impacting overall survival (OS). The findings are expected to be a reference for clinicians in managing advanced lung cancer patients.<h4>Methods</h4>Clinical characteristics from advanced EGFR-mutant NSCLC patients who received EGFR-TKIs were retrospectively analyzed to investigate th","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2025-04-04T00:32:47.901Z","creation":"2025-04-04T00:32:47.901Z"},"accession":"S-EPMC11907820","cross_references":{"pubmed":["40082918"],"doi":["10.1186/s12890-025-03569-1"]}}